Who are Recombinant Human Albumin Injection's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): GoodSense Eye Drops Advanced Relief Moisturizer, HES 130/04, HETASTARCH, Placebo: Human albumin 2.5%, HES 130/0.42 + electrolyte solution, balanced 6% hydroxyethylstarch 130/0.4.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/recombinant-human-albumin-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Recombinant Human Albumin Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Recombinant Human Albumin Injection (Recombinant Human Albumin Injection) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Plasma volume expander; recombinant protein therapeutic. Area: Critical Care; Hematology.

phase 3 Plasma volume expander; recombinant protein therapeutic Critical Care; Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Recombinant Human Albumin Injection (Recombinant Human Albumin Injection) — The First Hospital of Jilin University. Recombinant human albumin acts as a plasma volume expander and carrier protein to maintain oncotic pressure and transport endogenous substances.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Approval / PDUFA
Recombinant Human Albumin Injection TARGET	Recombinant Human Albumin Injection	The First Hospital of Jilin University	phase 3	Plasma volume expander; recombinant protein therapeutic
GoodSense Eye Drops Advanced Relief Moisturizer	DEXTRAN	Allergan	marketed	Plasma Volume Expander [EPC]	1978-01-01
HES 130/04	HES 130/04	K. C. Rasmussen	marketed	Synthetic colloid / Plasma volume expander
HETASTARCH	HETASTARCH		marketed	Plasma Volume Expander [EPC]
Placebo: Human albumin 2.5%	Placebo: Human albumin 2.5%	Baxalta now part of Shire	marketed	Plasma volume expander; colloid
HES 130/0.42 + electrolyte solution	HES 130/0.42 + electrolyte solution	B. Braun Melsungen AG	marketed	Synthetic colloid plasma volume expander
balanced 6% hydroxyethylstarch 130/0.4	balanced 6% hydroxyethylstarch 130/0.4	University Hospital Muenster	marketed	Synthetic colloid plasma volume expander

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Plasma volume expander; recombinant protein therapeutic class)

The First Hospital of Jilin University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Recombinant Human Albumin Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/recombinant-human-albumin-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab